Sk Biopharmaceuticals Co Ltd (326030.KS)
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc
Company Info
Highlights
₩7.28T
₩578.00B
₩536.35B
₩72,600.00 - ₩130,000.00
₩137,187.50
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Sk Biopharmaceuticals Co Ltd (326030.KS) returned -16.29% year-to-date (YTD) and 8.90% over the past 12 months.
326030.KS
-16.29%
-13.41%
-10.06%
8.90%
2.37%
N/A
N/A
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 326030.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -1.80% | 4.49% | -12.89% | 7.25% | -12.68% | -16.29% | |||||||
| 2024 | -7.37% | 4.19% | -5.37% | -4.47% | -2.51% | -9.25% | 10.58% | 34.19% | -9.57% | 13.37% | -12.30% | 7.45% | 10.66% |
| 2023 | 0.55% | -8.00% | -5.10% | 9.00% | 6.52% | 10.07% | 0.62% | 5.28% | 0.58% | -12.53% | 14.19% | 16.61% | 39.25% |
| 2022 | -22.02% | 8.05% | 9.65% | 2.23% | -5.56% | -13.61% | 4.14% | -8.21% | -20.53% | 2.11% | 26.68% | -2.04% | -25.82% |
| 2021 | -14.20% | -18.62% | -12.71% | 5.83% | 4.13% | 8.37% | -3.25% | 5.46% | -18.73% | -7.25% | 0.74% | 1.99% | -42.49% |
| 2020 | 43.31% | -10.16% | -4.28% | 1.92% | 17.55% | -9.87% | 33.07% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 326030.KS is 54, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Sk Biopharmaceuticals Co Ltd (326030.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sk Biopharmaceuticals Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sk Biopharmaceuticals Co Ltd was 76.13%, occurring on Oct 13, 2022. The portfolio has not yet recovered.
The current Sk Biopharmaceuticals Co Ltd drawdown is 57.14%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -76.13% | Jul 9, 2020 | 558 | Oct 13, 2022 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sk Biopharmaceuticals Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Sk Biopharmaceuticals Co Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -16.2%.
Valuation
The Valuation section provides an overview of how Sk Biopharmaceuticals Co Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 326030.KS relative to other companies in the Biotechnology industry. Currently, 326030.KS has a P/S ratio of 12.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 326030.KS in comparison with other companies in the Biotechnology industry. Currently, 326030.KS has a P/B value of 12.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |